The relationship between physical and psychological symptoms and health care utilization in hospitalized patients with advanced cancerRyan David Nipp, Jennifer S. Temel, Barbara J. Cashavelly et al.|Cancer|2017Cited by 237
End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin’s lymphomaJeffrey A. Barnes, Jeremy S. Abramson, Christiana E. Toomey et al.|Annals of Oncology|2010Cited by 105
Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trialMatthew S. Davids, Jennifer R. Brown, Danielle M. Brander et al.|The Lancet Haematology|2019Cited by 72
Initial Results of a Multicenter, Phase II Study of Ibrutinib Plus FCR (iFCR) As Frontline Therapy for Younger CLL PatientsMatthew S. Davids, Jennifer R. Brown, Haesook T. Kim et al.|Blood|2016Cited by 17
Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLLInhye E. Ahn, Matthew S. Davids, Danielle M. Brander et al.|Blood Advances|2024Cited by 12